DJIA 16,654.77 369.26 2.27%
NASDAQ 4,812.71 115.17 2.45%
S&P 500 1,987.66 47.15 2.43%
market minute promo


1.11 -0.01 (-0.89%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

VVUS $1.11 -0.89%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.13
Previous Close $1.12
Daily Range $1.10 - $1.15
52-Week Range $0.94 - $4.82
Market Cap $115.5M
P/E Ratio -1.10
Dividend (Yield) $0.00 (0.0%)
Volume 776,541
Average Daily Volume 1,734,836
Current FY EPS -$0.69




Drug Makers

VIVUS, Inc. (VVUS) Description

A pharmaceutical company dedicated to the development and commercialization of therapeutic products using patented proprietary formulations and novel delivery systems and by seeking new indications for previously approved pharmaceutical products. Website:

News & Commentary Rss Feed

The 3 Most Disappointing Drug Launches of All Time

Treatments with huge promise don't always pan out the way you'd expect.

Orexigen: Contrave Wins Another Sales Week - Don't Bank On Impressive Numbers

Vivus Hovers Near 52-Week Lows - Qsymia Sales Not Helping

This Is a Concern That Amgen Investors Shouldn't Take Lightly

Most investors are focused on the upcoming PDUFA decision for PCSK9 inhibitor Repatha, but this should be a far bigger concern.

Orexigen- Contrave Sales Win The Week But Still Flatter Than Needed

Arena - Belviq Sales Dip Again. We Have Seen The Peak In 2015

Vivus (VVUS) Flagged As Strong On High Volume

Stocks Trading Near Their 52-Week Lows: 4 Hot Picks

VIVUS Inc. (VVUS) in Focus: Stock Jumps 5.4%

VIVUS (VVUS) Is in Oversold Territory: What's Next?

See More VVUS News...

VVUS's Top Competitors

VVUS $1.11 (-0.89%)
Current stock: VVUS
JNJ $96.22 (1.17%)
Current stock: JNJ
NVS $98.64 (1.55%)
Current stock: NVS
RHHBY $34.85 (1.40%)
Current stock: RHHBY